Advertisement
Advertisement
U.S. Markets open in 3 hrs
Advertisement
Advertisement
Advertisement
Advertisement

Alector, Inc. (ALEC)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
22.93+0.99 (+4.51%)
At close: 04:00PM EST
22.93 0.00 (0.00%)
After hours: 05:39PM EST
Advertisement
Full screen
Loading interactive chart...
  • Benzinga

    Notable Alector Insider Makes $2.8M Sale

    Arnon Rosenthal, Insider at Alector (NASDAQ:ALEC), made a large insider sell on November 11, according to a new SEC filing. What Happened: A Form 4 filing from the U.S. Securities and Exchange Commission on Thursday showed that Rosenthal sold 110,000 shares of Alector at a price of $25.00. The total transaction amounted to $2,750,000. Following the transaction, Rosenthal still owns 3,428,101 shares of Alector worth $77,612,206. Alector shares are trading down 2.33% at $22.64 at the time of this

  • GlobeNewswire

    Alector Presents Encouraging New AL001 Data from the Symptomatic FTD-GRN Cohort of INFRONT-2 Phase 2 Open-label Clinical Study

    Progranulin Levels Increase to Normal Ranges Multiple Biomarkers of Disease Showed Improvement from Baseline with AL001 Treatment, Including GFAP, a Prognostic Marker for FTD Associated with Brain Atrophy FTD-GRN Patients Showed a Slowing of Clinical Progression with AL001 Treatment Relative to GENFI2 Matched Control Cohort Data from Phase 2 Study Presented at Clinical Trials of Alzheimer Disease Conference; Management to Host Webcast to Review Results Today at 4:00 p.m. ET BOSTON, Nov. 12, 2021

  • GlobeNewswire

    Alector Presents Preclinical Data from AL009 Multi-Siglec Inhibitor Program at the Society for Immunotherapy of Cancer’s 36th Annual Meeting

    Preclinical Oncology Program Highlights Alector’s Expertise in Harnessing Components of the Innate Immune System to Impact Disease AL009 Targets Innate Immune Checkpoint Receptors, Blocks Immune Suppression of Tumor Cells and Activates Potent Anti-Cancer Immune Response WASHINGTON, Nov. 12, 2021 (GLOBE NEWSWIRE) -- Alector, Inc. (Nasdaq: ALEC), a clinical-stage biotechnology company pioneering immuno-neurology, presented preclinical data from its AL009 immuno-oncology program in poster at the So

Advertisement
Advertisement